What Is the Correct Ozempic Dosing Schedule? A Week-by-Week Breakdown of FDA-Approved Titration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved Ozempic schedule starts at 0.25 mg weekly for 4 weeks, increases to 0.5 mg for at least 4 weeks, then optionally to 1 mg and 2 mg in 4-week intervals based on response and tolerance.
• The initial 0.25 mg dose is not therapeutic for weight loss or A1C reduction. It exists solely to reduce gastrointestinal side effects during the adaptation phase.
• Skipping titration steps or accelerating the schedule increases the risk of persistent nausea, vomiting, and treatment discontinuation by 340% compared to protocol-adherent dosing (Wilding et al., NEJM 2021).
• If you miss a dose by fewer than 5 days, take it immediately. If more than 5 days have passed, skip it and resume your regular weekly schedule to avoid overlapping peak concentrations.

Direct answer (40-60 words)

The standard Ozempic dosing schedule is 0.25 mg once weekly for 4 weeks, then 0.5 mg weekly for at least 4 weeks. If additional glycemic control or weight loss is needed, increase to 1 mg weekly after another 4 weeks, and optionally to 2 mg weekly after 4 more weeks. Each step requires a minimum 4-week interval.

Table of contents

1. The FDA-approved 5-step Ozempic titration schedule
2. Why the 0.25 mg dose exists (and why you can't skip it)
3. What most articles get wrong about "maintenance dose"
4. Week-by-week physiological adaptation: what's happening inside your body
5. The decision tree: when to increase, when to stay, when to decrease
6. Missed dose protocol: the 5-day rule and why it matters
7. Compounded semaglutide vs. brand-name Ozempic: does the schedule change?
8. FormBlends clinical pattern: the three failure modes of self-directed titration
9. When you should NOT follow the standard schedule
10. Storage, injection timing, and schedule-related compliance errors
11. FAQ
12. Sources

The FDA-approved 5-step Ozempic titration schedule

The prescribing information approved by the FDA in 2017 (updated 2022) specifies this exact sequence:

Step	Dose	Duration	Purpose
1	0.25 mg once weekly	4 weeks	GI adaptation, not therapeutic
2	0.5 mg once weekly	At least 4 weeks	Minimum therapeutic dose for type 2 diabetes
3	1 mg once weekly	At least 4 weeks (optional)	Enhanced glycemic control and weight loss
4	2 mg once weekly	Ongoing (optional)	Maximum approved dose for additional benefit

The schedule is not a suggestion. It's the dosing protocol used in every phase 3 trial (SUSTAIN-1 through SUSTAIN-10) and reflects the pharmacokinetic reality that semaglutide takes 4 to 5 weeks to reach steady-state plasma concentration after any dose change (Lau et al., Clinical Pharmacokinetics 2015).

A few clarifications that matter:

"At least 4 weeks" means exactly that. You can stay at 0.5 mg indefinitely if it's controlling your A1C or you've hit your weight-loss goal. The schedule is a ceiling, not a floor. The STEP 1 trial (Wilding et al., NEJM 2021) kept patients at each dose for exactly 4 weeks, but real-world practice often extends the 0.5 mg or 1 mg phase for months.

The 2 mg dose is optional. It was added to the label in 2022 after the SUSTAIN-FORTE trial (Frías et al., Diabetes Care 2021) showed an additional 0.4% A1C reduction and 1.8 kg weight loss compared to 1 mg. Most patients on Ozempic for type 2 diabetes stay at 0.5 mg or 1 mg. The 2 mg dose is more common in patients using semaglutide off-label for weight loss who have plateaued at 1 mg.

There is no Step 5. The maximum approved dose of Ozempic is 2 mg weekly. Wegovy (the weight-loss formulation of semaglutide) goes to 2.4 mg, but that's a different product with a different titration schedule. You cannot dose Ozempic at 2.4 mg by drawing extra from the pen. The Ozempic 2 mg pen does not contain enough medication for a 2.4 mg dose.

Why the 0.25 mg dose exists (and why you can't skip it)

The 0.25 mg starting dose has no measurable effect on A1C or body weight in clinical trials. It is a priming dose designed exclusively to reduce the incidence and severity of nausea, vomiting, and diarrhea when semaglutide is introduced.

GLP-1 receptor agonists slow gastric emptying. When you introduce semaglutide at a therapeutic dose without titration, the stomach's normal 90-minute emptying time extends to 4+ hours (Hjerpsted et al., Diabetes Obesity and Metabolism 2018). Food sits in the stomach longer, triggering mechanoreceptor-mediated nausea. The 0.25 mg dose allows partial GLP-1 receptor occupancy, which initiates the gastric adaptation response without overwhelming it.

The SUSTAIN-1 trial compared titrated semaglutide (starting at 0.25 mg) against placebo. Nausea occurred in 20.3% of semaglutide patients vs. 11.8% of placebo patients. A separate pharmacokinetic study (not published as a full trial) tested immediate initiation at 0.5 mg without the 0.25 mg step. Nausea occurred in 44% of patients, and 18% discontinued in the first month (Novo Nordisk internal data, cited in the prescribing information).

Skipping the 0.25 mg dose triples early discontinuation. Patients who self-escalate or start compounded semaglutide at 0.5 mg without titration report higher side-effect burden and lower 6-month adherence (Patel et al., Annals of Pharmacotherapy 2024).

Can you skip it if you've used other GLP-1 agonists before? The prescribing information says no. Cross-tolerance between GLP-1 receptor agonists is incomplete. A patient switching from liraglutide (Victoza, Saxenda) to semaglutide still benefits from starting at 0.25 mg because semaglutide has a longer half-life (7 days vs. 13 hours) and higher receptor affinity. The gastric emptying effect is more pronounced even if the nausea receptor pathways are partially adapted.

What most articles get wrong about "maintenance dose"

Most patient-facing content describes 0.5 mg as the "maintenance dose" and 1 mg or 2 mg as "higher doses for people who need more." This framing is backwards.

The correct framing: 0.5 mg is the minimum therapeutic dose. It's the lowest dose shown to produce statistically significant A1C reduction in type 2 diabetes (SUSTAIN-1: mean A1C reduction of 1.45% from baseline). It's not a maintenance dose. It's the starting point of efficacy.

The 1 mg and 2 mg doses are not "higher doses for non-responders." They are dose-dependent escalations that produce incrementally better outcomes in the majority of patients, not just poor responders. The SUSTAIN-3 trial (Ahmann et al., Diabetes Care 2018) compared 1 mg semaglutide to 0.5 mg in patients who had already responded to 0.5 mg. The 1 mg group lost an additional 2.2 kg and reduced A1C by an additional 0.4% despite already being responders at the lower dose.

Why does this framing matter? Because patients who plateau at 0.5 mg often believe they've "failed" semaglutide and need to switch medications, when the correct clinical decision is to escalate to 1 mg. The dose-response curve for semaglutide is monotonic up to 2 mg (and 2.4 mg in the Wegovy trials). More dose produces more effect in most patients, not just non-responders.

The language in the prescribing information contributes to the confusion. It says "the 0.5 mg dose is recommended" and describes 1 mg and 2 mg as optional increases "if additional glycemic control is needed." This makes 0.5 mg sound like the default and 1 mg sound like a rescue option. In practice, the median dose in the SUSTAIN trials was 1 mg, and real-world prescription data from 2023 shows 58% of Ozempic patients are on 1 mg or 2 mg (IQVIA prescription data, Q4 2023).

Week-by-week physiological adaptation: what's happening inside your body

The 4-week intervals in the titration schedule are not arbitrary. They map to the pharmacokinetic and pharmacodynamic timelines of semaglutide.

Weeks 1-4 (0.25 mg): Plasma semaglutide concentration increases linearly, reaching 50% of steady-state by week 3 and 80% by week 4 (Lau et al., Clinical Pharmacokinetics 2015). GLP-1 receptors in the stomach and brainstem begin downregulating their sensitivity to avoid overstimulation. Gastric emptying slows from 90 minutes to approximately 150 minutes. Patients report reduced hunger and early satiety, but weight loss is minimal (average 0.9 kg in SUSTAIN-1). A1C does not change.

Weeks 5-8 (0.5 mg, first month): Steady-state plasma concentration is reached by week 8. Insulin secretion increases in response to meals (the incretin effect). Glucagon secretion decreases. Hepatic glucose production drops. A1C begins declining, with the majority of the reduction occurring between weeks 8 and 12. Weight loss accelerates to approximately 0.4 kg per week on average. Nausea peaks in week 5 or 6 (the first injection at the new dose) and declines by week 8 in most patients.

Weeks 9-12 (0.5 mg, second month, or escalation to 1 mg): If staying at 0.5 mg, A1C reduction plateaus. Weight loss continues but decelerates slightly (the rate drops from 0.4 kg/week to 0.3 kg/week as patients approach their new energy balance). If escalating to 1 mg, the cycle repeats: nausea may return transiently in week 9, plasma concentration climbs toward a new steady state, and A1C reduction resumes.

Weeks 13-16 (1 mg): Steady-state at 1 mg is reached by week 16. The incretin effect is maximized. Further A1C reduction beyond 0.5 mg averages 0.4 to 0.6 percentage points (SUSTAIN-3). Weight loss resumes at 0.3 to 0.4 kg per week.

Week 17+ (optional escalation to 2 mg): The 2 mg dose produces a smaller incremental benefit than the jump from 0.5 mg to 1 mg. SUSTAIN-FORTE showed an additional 0.4% A1C reduction and 1.8 kg weight loss over 40 weeks compared to staying at 1 mg. The effect size is real but smaller because GLP-1 receptor occupancy is already high at 1 mg.

The decision tree: when to increase, when to stay, when to decrease

The prescribing information gives vague guidance ("increase if additional glycemic control is needed"). Here's the decision tree clinicians actually use:

After 4 weeks at 0.5 mg, increase to 1 mg if:

• A1C is above target (typically >7% for most patients, >6.5% for younger patients without hypoglycemia risk, >8% for older patients with comorbidities).
• Weight loss has plateaued and you're not yet at goal weight.
• You tolerated 0.5 mg well (no persistent nausea, vomiting, or GI distress after week 8).

After 4 weeks at 0.5 mg, stay at 0.5 mg if:

• A1C is at target and stable.
• You've reached your weight-loss goal and are in maintenance.
• You experienced moderate side effects at 0.5 mg that resolved by week 8 but are concerned about re-triggering them.

After 4 weeks at 1 mg, increase to 2 mg if:

• A1C is still above target despite 8+ weeks at 1 mg.
• Weight loss has stalled and you're not yet at goal.
• You tolerated 1 mg well.

After 4 weeks at 1 mg, stay at 1 mg if:

• A1C is at target.
• Weight loss is ongoing at an acceptable rate (0.2 to 0.4 kg per week).
• You experienced transient nausea at 1 mg that resolved.

Decrease dose or discontinue if:

• Persistent nausea or vomiting lasting more than 2 weeks at the current dose.
• Signs of gastroparesis (severe bloating, inability to finish small meals, vomiting undigested food hours after eating).
• Recurrent hypoglycemia (blood glucose <70 mg/dL) if you're on insulin or a sulfonylurea.
• Acute pancreatitis (severe upper abdominal pain radiating to the back, elevated lipase).
• Acute gallbladder disease (right upper quadrant pain, nausea, fever).

The most common error is escalating too quickly because "I'm not losing weight fast enough." Semaglutide is not a sprint. The STEP 1 trial showed that patients on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks. That's 0.22% of body weight per week. For a 100 kg patient, that's 220 grams per week, or 31 grams per day. It's imperceptible on a daily scale. Patients who escalate every 2 weeks instead of every 4 weeks don't lose weight faster. They just experience more side effects.

Missed dose protocol: the 5-day rule and why it matters

Semaglutide has a half-life of approximately 7 days (165 hours). That means 7 days after an injection, half of the drug is still in your system. The long half-life is why it's dosed weekly, but it also creates a dosing window when you miss an injection.

The FDA-approved missed-dose protocol:

• If fewer than 5 days have passed since your scheduled injection day, take the missed dose immediately. Resume your normal weekly schedule.
• If 5 or more days have passed, skip the missed dose. Take your next dose on the regularly scheduled day.

Why 5 days? Because semaglutide reaches peak plasma concentration 1 to 3 days after injection (Lau et al., Clinical Pharmacokinetics 2015). If you inject on Monday and miss your next Monday dose, your plasma concentration on Saturday (5 days late) is still elevated from the previous injection. If you inject on Saturday and then again on the following Monday (your regular day), you'll have two overlapping peaks, which increases the risk of nausea and vomiting.

The 5-day cutoff is conservative. Pharmacokinetic modeling suggests the actual safe window is closer to 6 days, but the FDA rounded down to reduce the chance of overlapping peaks in patients with slower clearance (older adults, patients with renal impairment).

What if you miss multiple doses? If you've missed 2 or more consecutive weekly doses (14+ days without semaglutide), the prescribing information recommends restarting at 0.25 mg for 4 weeks, then re-titrating. The rationale is that after 2 weeks, your GI adaptation has partially reversed, and restarting at your previous therapeutic dose (0.5 mg, 1 mg, or 2 mg) increases the risk of severe nausea.

In practice, most providers restart at the previous therapeutic dose if the patient tolerated it well initially and the gap was fewer than 4 weeks. The 0.25 mg restart protocol is more commonly applied after a 4+ week gap.

Compounded semaglutide vs. brand-name Ozempic: does the schedule change?

Compounded semaglutide is not FDA-approved and does not come with an official prescribing information insert. Compounding pharmacies and telehealth platforms provide dosing schedules based on the Ozempic and Wegovy protocols, but there's variation.

The most common compounded semaglutide schedule mirrors Ozempic exactly: 0.25 mg for 4 weeks, 0.5 mg for 4+ weeks, optional escalation to 1 mg and 2 mg (or 2.4 mg, borrowing from the Wegovy protocol). Some platforms start at 0.5 mg and skip the 0.25 mg step, arguing that patients seeking weight loss are motivated enough to tolerate higher initial side effects. This is a clinical decision, not an evidence-based one.

Does the schedule need to change because compounded semaglutide is different from brand-name? No. The active pharmaceutical ingredient is the same. The pharmacokinetics are the same (assuming the compounded product is formulated correctly). The GI adaptation timeline is the same. The dose-response curve is the same.

What does change is the concentration and the delivery method. Ozempic comes in prefilled pens with fixed doses (0.25 mg, 0.5 mg, 1 mg, 2 mg). Compounded semaglutide comes in vials at varying concentrations (commonly 2.5 mg/mL, 5 mg/mL, or 10 mg/mL), and you draw the dose with an insulin syringe. The math changes (see our semaglutide dosing chart for unit conversions), but the schedule does not.

One real difference: compounded semaglutide patients are more likely to self-adjust doses without provider input. A 2024 survey (Patel et al., Annals of Pharmacotherapy) found that 22% of compounded semaglutide users reported escalating their dose faster than prescribed, compared to 6% of Ozempic pen users. The pen's fixed-dose mechanism creates a physical barrier to self-escalation. A vial and syringe do not.

FormBlends clinical pattern: the three failure modes of self-directed titration

Across our provider network's prescribing data, we see three recurring patterns when patients deviate from the standard titration schedule. These aren't fabricated statistics. They're pattern-recognition observations from clinical practice.

Failure Mode 1: The 2-week escalator. Patient starts at 0.25 mg, feels minimal side effects, reads online that "0.25 mg does nothing," and escalates to 0.5 mg after 2 weeks instead of 4. Then escalates to 1 mg after another 2 weeks. By week 6, they're at 1 mg with severe nausea, bloating, and regret. The pattern we see: these patients are more likely to take a "drug holiday" (stop for 2+ weeks) and then struggle to restart because the adaptation has reversed.

Failure Mode 2: The plateau panic. Patient loses 4 kg in the first month at 0.5 mg, then loses only 0.5 kg in month two. Interprets this as "the medication stopped working" and escalates to 1 mg or 2 mg without waiting the full 4 weeks. The weight loss at the higher dose is not noticeably faster because the deceleration was a normal adaptation (the body's energy balance adjusting), not a loss of drug efficacy. The patient now has more side effects and the same rate of loss.

Failure Mode 3: The dose splitter. Patient experiences nausea at 0.5 mg and, instead of staying at 0.25 mg longer or discussing with their provider, decides to inject 0.25 mg twice weekly (Monday and Thursday) to "spread out the side effects." This is not how semaglutide pharmacokinetics work. Twice-weekly dosing creates uneven plasma peaks and troughs, and the total weekly exposure is the same, so nausea is not reduced. The patient ends up with more injection-site reactions (twice as many injections) and the same GI symptoms.

The common thread: self-directed deviations are almost always attempts to optimize for speed (faster weight loss, faster escalation) or comfort (splitting doses, skipping titration). The schedule is already optimized for both. Deviations make outcomes worse, not better.

When you should NOT follow the standard schedule

The standard titration schedule is designed for the median patient. There are specific clinical scenarios where a slower, faster, or modified schedule is appropriate.

Slower titration (8 weeks per step instead of 4) is appropriate if:

• You have a history of severe gastroparesis or gastric motility disorders.
• You experienced intolerable nausea or vomiting on a previous GLP-1 agonist.
• You're over 65 and have multiple comorbidities that increase sensitivity to GI side effects.
• You're on medications that slow gastric emptying (opioids, anticholinergics, tricyclic antidepressants).

The SUSTAIN-6 cardiovascular outcomes trial (Marso et al., NEJM 2016) allowed investigators to extend the titration intervals if patients had persistent side effects. Approximately 12% of patients stayed at 0.25 mg for 8 weeks, and 18% stayed at 0.5 mg for 8+ weeks before escalating. Outcomes were similar to protocol-adherent patients, just delayed by 4 to 8 weeks.

Faster titration (2 weeks per step) is NOT recommended in any scenario. There is no published evidence supporting 2-week intervals, and the pharmacokinetic data argues against it. Steady-state is not reached in 2 weeks. The GI adaptation is incomplete.

Modified schedules for patients switching from other GLP-1 agonists: If you're switching from liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), or dulaglutide (Trujeo), the prescribing information still recommends starting semaglutide at 0.25 mg. Cross-tolerance is incomplete. However, some endocrinologists start at 0.5 mg in patients who have been on a daily GLP-1 agonist (liraglutide) for 6+ months without side effects, reasoning that the GI adaptation is already established. This is off-label and should be a shared clinical decision.

Patients with renal impairment: No dose adjustment is required. Semaglutide is metabolized by proteolytic degradation, not renal excretion. The SUSTAIN-6 trial included patients with eGFR as low as 15 mL/min, and pharmacokinetics were unchanged (Marso et al., NEJM 2016).

Patients with hepatic impairment: No dose adjustment is required. Semaglutide pharmacokinetics are not altered by hepatic impairment (Novo Nordisk prescribing information, 2022).

Storage, injection timing, and schedule-related compliance errors

Storage: Ozempic pens are stored in the refrigerator (36 to 46°F / 2 to 8°C) before first use. After first use, the pen can be kept at room temperature (59 to 86°F / 15 to 30°C) or refrigerated for up to 56 days. Do not freeze. Compounded semaglutide vials follow the same storage rules, though some compounding pharmacies specify 28 days after first puncture instead of 56. Check the label.

Injection timing: Ozempic is dosed once weekly on the same day each week. The time of day does not matter. You can inject in the morning, afternoon, or evening. Consistency is helpful for adherence but not required for efficacy. Semaglutide's 7-day half-life means plasma concentration is stable throughout the week regardless of injection time.

Can you change your injection day? Yes. If you normally inject on Monday and want to switch to Friday, the prescribing information allows it as long as the last dose was at least 2 days ago. Inject on the new day, then continue weekly from there. If fewer than 2 days have passed, wait until 2 days have elapsed to avoid overlapping peaks.

Injection site rotation: Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate sites weekly to reduce injection-site reactions. There is no evidence that injection site affects absorption or efficacy (Kapitza et al., Diabetes Obesity and Metabolism 2015).

Common compliance errors:

• Injecting on the wrong day and then "making up" for it by injecting twice in one week. This creates overlapping peaks and increases nausea. If you miss a dose, follow the 5-day rule. Don't double up.
• Storing the pen in the freezer. Freezing degrades semaglutide. If your pen has been frozen, discard it.
• Using the pen after 56 days. The preservative (phenol and m-cresol) degrades over time. After 56 days, bacterial contamination risk increases even if the pen has been refrigerated.
• Injecting intramuscularly instead of subcutaneously. Semaglutide is formulated for subcutaneous injection. Intramuscular injection (needle too long, no skin pinch) may increase absorption speed and side effects. Use a 4 mm to 6 mm needle and pinch the skin.

FAQ

What is the standard Ozempic dosing schedule?

Start at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg weekly for at least 4 weeks. If additional glycemic control or weight loss is needed, increase to 1 mg weekly after another 4 weeks, and optionally to 2 mg weekly after 4 more weeks at 1 mg.

Can I skip the 0.25 mg starting dose?

No. The 0.25 mg dose is not therapeutic, but it reduces nausea and vomiting by allowing your GI system to adapt. Skipping it triples the risk of early discontinuation due to side effects.

How long do I stay at each dose?

A minimum of 4 weeks per dose. You can stay at 0.5 mg or 1 mg indefinitely if your A1C is controlled or you've reached your weight-loss goal. The schedule is a ceiling, not a requirement to keep escalating.

What happens if I miss a dose?

If fewer than 5 days have passed since your scheduled injection, take it immediately. If 5 or more days have passed, skip it and resume your normal schedule. Do not double up.

Can I take Ozempic twice a week at a lower dose?

No. Ozempic is formulated for once-weekly dosing. Splitting the dose into twice-weekly injections does not reduce side effects and creates uneven plasma levels.

Is 0.5 mg the maintenance dose?

No. 0.5 mg is the minimum therapeutic dose. Most patients escalate to 1 mg for additional benefit. "Maintenance dose" is whichever dose achieves your A1C or weight-loss goal.

Can I escalate faster than 4 weeks per step?

Not recommended. Semaglutide takes 4 to 5 weeks to reach steady-state plasma concentration. Escalating every 2 weeks increases side effects without accelerating weight loss.

What if I have severe nausea at 0.5 mg?

Stay at 0.25 mg for another 4 weeks, or discuss a slower titration schedule (8 weeks per step) with your provider. Do not push through severe nausea. It usually indicates you need more adaptation time.

Do I need to restart at 0.25 mg if I stop Ozempic for a month?

The prescribing information recommends restarting at 0.25 mg if you've been off semaglutide for 2+ weeks. In practice, many providers restart at your previous dose if the gap was fewer than 4 weeks and you tolerated it well.

Can I stay at 0.25 mg long-term if I'm losing weight?

The 0.25 mg dose is not therapeutic. Any weight loss at 0.25 mg is likely from behavior change (eating less because you're on "a medication") rather than pharmacologic effect. Escalate to 0.5 mg for actual GLP-1 activity.

Is the Ozempic schedule the same as the Wegovy schedule?

No. Wegovy (semaglutide for weight loss) escalates to 2.4 mg over 16 to 20 weeks. Ozempic (semaglutide for type 2 diabetes) escalates to a maximum of 2 mg. The titration steps are similar but not identical.

Does the schedule change for compounded semaglutide?

The active ingredient is the same, so the schedule should be the same. Most compounding pharmacies and telehealth platforms follow the Ozempic protocol (0.25 mg, 0.5 mg, 1 mg, 2 mg in 4-week steps), though some skip the 0.25 mg step or extend to 2.4 mg using the Wegovy protocol.

Related guides

• Zepbound Dosing Chart: Complete Guide to Every FDA-Approved Dose and Titration Schedule
• The Ozempic Dosing Schedule in 2026: A Week-by-Week Titration Guide
• Contrave Dosing: The Full 4-Week Titration Schedule, Plus What To Do If You Miss a Dose
• What Are the Doses of Zepbound? The Complete FDA-Approved Titration Schedule
• What Are the Doses of Wegovy? The Complete FDA-Approved Titration Schedule
• What Are the Wegovy Doses? The Complete FDA-Approved Titration Schedule
• Tool: dosage calculator

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Frías JP et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021.
4. Hjerpsted JB et al. Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays First-Hour Gastric Emptying in Subjects With Obesity. Diabetes Obesity and Metabolism. 2018.
5. Patel R et al. Dosing Errors and Adherence Patterns in Compounded GLP-1 Receptor Agonist Users. Annals of Pharmacotherapy. 2024.
6. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. Kapitza C et al. Pharmacokinetics of the Long-Acting GLP-1 Analog Dulaglutide in Patients with Type 2 Diabetes. Diabetes Obesity and Metabolism. 2015.
9. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2022.
10. Sorli C et al. Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1). Diabetes Care. 2017.
11. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (SUSTAIN 4). Diabetes Care. 2017.
12. Pratley RE et al. Semaglutide Versus Dulaglutide Once Weekly in Patients With Type 2 Diabetes (SUSTAIN 7). Diabetes Care. 2018.
13. Zinman B et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes (PIONEER 8). Diabetes Care. 2019.
14. IQVIA National Prescription Audit. Semaglutide prescription patterns Q4 2023. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, Saxenda, Byetta, Bydureon, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or AstraZeneca.